Fludarabine (NSC 118218)

For research use only. Not for use in humans.

目录号：S1491 别名： FaraA, Fludarabinum 中文名称：氟达拉滨

Fludarabine (NSC 118218) Chemical Structure

CAS No. 21679-14-1

Fludarabine (NSC 118218, FaraA, Fludarabinum)在血管平滑肌细胞中是一种STAT1活化抑制剂，特异性降低STAT1蛋白质水平（和mRNA水平），而对其他STATs无此作用。它还是一种DNA合成抑制剂。Fludarabine可诱导凋亡。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 1032.75	现货
10mg	RMB 810.59	现货
50mg	RMB 2525.07	现货
100mg	RMB 3836.33	现货
200mg	RMB 7289.1	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的Fludarabine (NSC 118218)发表文献100篇：

Cell, 2020, 182(3):685-712.e19

PubMed: 32645325 ( click the link to review the publication )

Cell Metab, 2020, 31(3):564-579

PubMed: 32130883 ( click the link to review the publication )

Nat Chem Biol, 2018, 14(10):943-954

PubMed: 30150681 ( click the link to review the publication )

Cancer Cell, 2018, 34(5):757-774

PubMed: 30423296 ( click the link to review the publication )

Cell Rep, 2021, 34(1):108584

PubMed: 33406422 ( click the link to review the publication )

Ann Transl Med, 2021, 9(5):365

PubMed: 33842586 ( click the link to review the publication )

Clinics (Sao Paulo), 2021, 76:e2348

PubMed: 33681944 ( click the link to review the publication )

Liver Int, 2021, 10.1111/liv.14816

PubMed: 33555112 ( click the link to review the publication )

Cell Res, 2020, 1-10

PubMed: 33159154 ( click the link to review the publication )

Sci Adv, 2020, 29;6(18):eaax7881

PubMed: 32494661 ( click the link to review the publication )

Cell Rep, 2020, 31(13):107825

PubMed: 32610126 ( click the link to review the publication )

Haematologica, 2020, 16 pii: haematol

PubMed: 32299906 ( click the link to review the publication )

J Exp Clin Cancer Res, 2020, 39(1):228

PubMed: 33115525 ( click the link to review the publication )

Br J Cancer, 2020, 18

PubMed: 32418995 ( click the link to review the publication )

Signal Transduct Target Ther, 2020, 5(1):34

PubMed: 32296043 ( click the link to review the publication )

Signal Transduct Target Ther, 2020, 10;5:34

PubMed: 32284883 ( click the link to review the publication )

Cell Chem Biol, 2020, 27(1):122-133

PubMed: 31836351 ( click the link to review the publication )

Front Immunol, 2020, 14;11:867

PubMed: 32477351 ( click the link to review the publication )

Cell Commun Signal, 2020, 18(1):30

PubMed: 32093731 ( click the link to review the publication )

Exp Neurol, 2020, S0014-4886(20)30337-X

PubMed: 33065077 ( click the link to review the publication )

Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )

Life Sci, 2020, 265:118832

PubMed: 33259866 ( click the link to review the publication )

Cardiovasc Diagn Ther, 2020, 10(4):738-751

PubMed: 32968630 ( click the link to review the publication )

Scand J Immunol, 2020, e12981

PubMed: 33031600 ( click the link to review the publication )
Hum Cell, 2020, 10.1007/s13577-020-00425-8

PubMed: 32886306 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00420-z

PubMed: 32870449 ( click the link to review the publication )

Clin Exp Pharmacol Physiol, 2020, 4

PubMed: 32248559 ( click the link to review the publication )

Exp Lung Res, 2020, 1-9

PubMed: 33238771 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2020, 146(2):329-342

PubMed: 31912229 ( click the link to review the publication )

PLoS One, 2020, 15(7):e0228302

PubMed: 32628668 ( click the link to review the publication )

Int J Cancer, 2020, 10.1002/ijc.33202

PubMed: 32638373 ( click the link to review the publication )

Front Immunol, 2020, 11:1303

PubMed: 32655571 ( click the link to review the publication )

Microb Pathog, 2020, 142:104112

PubMed: 32126255 ( click the link to review the publication )

Int J Biol Macromol, 2020, 147:616-628

PubMed: 31931060 ( click the link to review the publication )

Cell Mol Immunol, 2020, 10.1038/s41423-019-0345-7

PubMed: 31900460 ( click the link to review the publication )

Cancer Immunol Res, 2020, 8(3):292-308

PubMed: 32024640 ( click the link to review the publication )

J Microbiol Immunol Infect, 2020, 25 pii: S1684-1182(20)30001-3

PubMed: 32033858 ( click the link to review the publication )

Stem Cell Res Ther, 2020, 11(1):112

PubMed: 32169104 ( click the link to review the publication )

Blood, 2019, 134(21):1821-1831

PubMed: 31527074 ( click the link to review the publication )

Nat Chem Biol, 2019, 15(3):232-240

PubMed: 30692684 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2189

PubMed: 31097698 ( click the link to review the publication )

Mucosal Immunol, 2019, 10.1038/s41385-019-0178-9

PubMed: 31182817 ( click the link to review the publication )

Redox Biol, 2019, 24:101189

PubMed: 30986607 ( click the link to review the publication )

Cancer Lett, 2019, 10.1016/j.canlet.2019.07.016

PubMed: 31352079 ( click the link to review the publication )

PLoS Pathog, 2019, 15(11):e1008037

PubMed: 31725811 ( click the link to review the publication )

Mol Ther Oncolytics, 2019,

PubMed: 30775418 ( click the link to review the publication )

Front Immunol, 2019, 10:1622

PubMed: 31379827 ( click the link to review the publication )

Am J Cancer Res, 2019, 9(12):2618-2633

PubMed: 31911850 ( click the link to review the publication )
J Immunol, 2019, 202(11):3173-3186

PubMed: 30996000 ( click the link to review the publication )

Int J Biol Macromol, 2019, 136:980-993

PubMed: 31220493 ( click the link to review the publication )

Respir Res, 2019, 20(1):184

PubMed: 31416461 ( click the link to review the publication )

Life Sci, 2019, 10.1016/j.lfs.2019.116583

PubMed: 31226417 ( click the link to review the publication )

Gut Pathog, 2019, 11:23

PubMed: 31123503 ( click the link to review the publication )

Immunobiology, 2019, 224(3):388-396

PubMed: 30846331 ( click the link to review the publication )

Appl Health Econ Health Policy, 2019, 17(6):827-839

PubMed: 31392669 ( click the link to review the publication )

J Microbiol Immunol Infect, 2019, S1684-1182(18)30306-2

PubMed: 31296484 ( click the link to review the publication )

Cancer Immunol Res, 2019, 7(12):1944-1957

PubMed: 31554639 ( click the link to review the publication )

Hepatology, 2018, 10.1002/hep.30317

PubMed: ( click the link to review the publication )

J Cell Biol, 2018, 217(4):1503-1519

PubMed: 29507126 ( click the link to review the publication )

Mol Syst Biol, 2018, 14(3):e7858

PubMed: 29507054 ( click the link to review the publication )

Oncogene, 2018, 37(17):2270-2284

PubMed: 29391602 ( click the link to review the publication )

Cell Death Dis, 2018, 9(5):459

PubMed: 29686406 ( click the link to review the publication )

Br J Cancer, 2018, 118(4):509-521

PubMed: 29348488 ( click the link to review the publication )

Expert Opin Ther Targets, 2018, 22(6):547-557

PubMed: 29702007 ( click the link to review the publication )

J Virol, 2018, 92(22)e00728-18

PubMed: 30185587 ( click the link to review the publication )

Hum Immunol, 2018, 79(12):869-875

PubMed: 30316971 ( click the link to review the publication )

Oncotarget, 2018, 9(10):9273-9284

PubMed: 29507689 ( click the link to review the publication )

Neuron, 2017, 96(6):1290-1302

PubMed: 29268096 ( click the link to review the publication )

Nat Commun, 2017, 8:15207

PubMed: 28488695 ( click the link to review the publication )

Nat Commun, 2017, 8:15776

PubMed: 28585539 ( click the link to review the publication )

Leukemia, 2017, 31(2):340-349

PubMed: 27431016 ( click the link to review the publication )

Cancer Res, 2017, 77(15):4135-4145

PubMed: 28615225 ( click the link to review the publication )
Brain Behav Immun, 2017, 60:161-173

PubMed: 27742579 ( click the link to review the publication )

Mol Cancer Res, 2017, 15(5):585-597

PubMed: 28108623 ( click the link to review the publication )

Sci Rep, 2017,

PubMed: 29259270 ( click the link to review the publication )

Sci Rep, 2017, 7(1):14416

PubMed: 29089548 ( click the link to review the publication )

Clin Immunol, 2017, 175:56-68

PubMed: 27940139 ( click the link to review the publication )

J Cell Biochem, 2017, 118(10):3249-3259

PubMed: 28262979 ( click the link to review the publication )

Inflammation, 2017, 40(5):1726-1734

PubMed: 28656529 ( click the link to review the publication )

Mol Med Rep, 2017, 16(6):9111-9119

PubMed: 28990062 ( click the link to review the publication )

PLoS One, 2017, 12(6):e0180244

PubMed: 28665978 ( click the link to review the publication )

J Clin Invest, 2016, 126(1):181-94

PubMed: 26619119 ( click the link to review the publication )

J Exp Med, 2016, 19;213(10):2209-26

PubMed: 27621415 ( click the link to review the publication )

Cancer Res, 2016, 76(4):818-30

PubMed: 26837767 ( click the link to review the publication )

Int Immunopharmacol, 2016, 36:199-204

PubMed: 27160867 ( click the link to review the publication )

FEBS Lett, 2016, 590(1):53-67

PubMed: 26762170 ( click the link to review the publication )

Biogerontology, 2016, 17(5-6):907-920

PubMed: 27484416 ( click the link to review the publication )

Oncotarget, 2016, 8(31):50570-50581

PubMed: 28881584 ( click the link to review the publication )

EMBO Mol Med, 2015, 10.15252/emmm.201404580

PubMed: 25759362 ( click the link to review the publication )

Eur J Immunol, 2015, 45(10):2834-46

PubMed: 26255980 ( click the link to review the publication )

Phytother Res, 2015, 29(7):1088-96

PubMed: 25881570 ( click the link to review the publication )

Int Immunopharmacol, 2015, 28(1):61-9

PubMed: 26044347 ( click the link to review the publication )

Mol Med Rep, 2015, 12(6):7869-76

PubMed: 26497667 ( click the link to review the publication )

Oncotarget, 2015, 6(41):43992-4004

PubMed: 26556857 ( click the link to review the publication )

Basic Res Cardiol, 2014, 109(4):419

PubMed: 24907869 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1512

PubMed: 25375377 ( click the link to review the publication )
Mol Cancer Ther, 2014, 13(10):2276-87

PubMed: 25122069 ( click the link to review the publication )

J Biol Chem, 2014, 289(14):9952-60

PubMed: 24550394 ( click the link to review the publication )

Mol Cell Biol, 2014, 34(24):4368-78

PubMed: 25312644 ( click the link to review the publication )

Mol Cancer Ther, 2013, 12(7):1299-309

PubMed: 23657945 ( click the link to review the publication )

产品安全说明书

STAT抑制剂选择性比较

生物活性

产品描述

靶点

STAT1 ^[4]
(Vascular smooth muscle cells)

体外研究

Fludarabine有效抑制RPMI8226细胞增殖,呈时间浓度依赖性。Fludarabine处理MM.1S和MM.1R细胞48小时的IC50分别为13.48μg/mL和33.79μg/mL。而Fludarabine处理U266细胞48小时的IC 50为222.2μg/mL。Fludarabine处理可增加处于细胞周期G 1期的细胞数量，并伴随着处于细胞周期S期细胞数量的减少，对细胞周期的影响呈时间依赖性。Fludarabine在MM细胞中诱导细胞周期阻滞和细胞凋亡。Fludarabine时间依赖性的诱导caspase，-8，- 9和- 3，- 7的剪切，继而诱导PARP的剪切。氟达拉滨以时间梯度增加Bax基因表达，而Bak基因表达量不变。RPMI 8226细胞用Fludarabine处理12小时，处理后细胞膜电位降低，61.05%的细胞表达低荧光罗丹明123，而未处理的对照组细胞仅为8.62%^[1]。为提高溶解度，Fludarabine可制为一磷酸盐形式(F-ara-AMP, fudarabine)，在静脉滴注后即可即时、定量的从母核上去磷酸化。细胞内重磷酸化修饰导致Fludarabine-阿糖胞苷三磷酸（(F-ara-ATP）。该代谢产物抑制了DNA复制的几个关键过程，如DNA合成所需酶，比如核糖核酸还原酶，DNA引发酶，DNA聚合酶，具有3 ' - 5 '外切酶活性的脱氧核糖核酸聚合酶δ和ε和DNA连接酶^[2]。通过检测ICAM - 1的表达和IL - 8释放，表明Fludarabine还可以诱导前炎症刺激单核细胞的增加^[3]。Fludarabine对卵巢癌细胞系生长无影响，而它对黑色素瘤细胞系有明显的剂量依赖性抑制^[4]。Fludarabine诱导显著降低STAT - 1磷酸化，但不改变JAK 2活性。磷酸Fludarabine对三种STAT蛋白磷酸化影响不显着。Fludarabine（1.5mg）在处理2天后和7天后显著降低磷酸化STAT - 1和STAT-1总蛋白量^[5]。磷酸化JAK 2在处理后第2天变化不明显，处理后第7天的JAK表达明显受抑制。Fludarabine不影响其他STAT蛋白质，特异性抑制STAT - 1激活以降低血管平滑肌细胞体外增殖。^[5]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
Jeko-1	M2\RW2Z2dmO2aX;uJGF{e2G7	MYeyNEDPxE1?	MVyyOEBp		MVnpcohq[mm2czDlfJBz\XO\|aX;uJI9nKEmGTx?=	NFT4O\|M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUm0NFcyOid-MkW5OFA4OTJ:L3G+
MV-4-11	NX3nSXVYSXCxcITvd4l{KEG\|c3H5	M3PtblIvPSEQvF2=	MX20PEBp		MnPZbY5lfWOnczDhdI9xfG:\|aYOgd4xq\2i2bIm=	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTFzMUW4N{c,OjVzMUG1PFM9N2F-
THP-1	MYfBdI9xfG:\|aYOgRZN{[Xl?	NF\EXIczNjVizszN	MnnTOFghcA>?		Mmf1bY5lfWOnczDhdI9xfG:\|aYOgd4xq\2i2bIm=	NGW2V4U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUGxNVU5Oyd-MkWxNVE2QDN:L3G+
MOLM 13	NUP1OoNLSXCxcITvd4l{KEG\|c3H5	MojjNk42KM7:TR?=	NWDh[JhjPDhiaB?=		M{\2W4lv\HWlZYOgZZBweHSxc3nzJJNtcWeqdHz5	NXPoZXNzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxNVE2QDNpPkK1NVEyPTh\|PD;hQi=>
KBM3/Bu2506	NU\pSHVpSXCxcITvd4l{KEG\|c3H5	MkTHNk42KM7:TR?=	NIrzUmY1QCCq		M1fWdIlv\HWlZYOgZZBweHSxc3nzJJNtcWeqdHz5	NEm5d5I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUGxNVU5Oyd-MkWxNVE2QDN:L3G+
Nalm-6	NHL3PVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4[1dWlEPTB;MUig{txO	M3L3[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3ME[xNVAyLz5{NUC2NVExOTxxYU6=
Reh	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkXzTWM2OD1\|MDFOwG0>	M32wclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3ME[xNVAyLz5{NUC2NVExOTxxYU6=
U2937	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M13xeWlEPTB;MU[g{txO	M4jQfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3ME[xNVAyLz5{NUC2NVExOTxxYU6=
Mec-1	Mm\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{Wwc2lEPTExvK61NFAh\|ryP	MkTQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyNkGxNFEoRjJ3ME[xNVAyRC:jPh?=
RPMI-8226	M1LWW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4fOVmlEPTB;NUCwJO69VQ>?	NFnTXXQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUC2NVExOSd-MkWwOlEyODF:L3G+
Molt-4	NGn2eVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn;nTWM2OD1zOECg{txO	NHXwSWI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUC2NVExOSd-MkWwOlEyODF:L3G+
Nalm-6-FluR	M4rodmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmXrTWM2OD1{NUCg{txO	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTB4MUGwNUc,OjVyNkGxNFE9N2F-
Raji	M13qS2Z2dmO2aX;uJGF{e2G7	MoH1N:Kh\|ryP	MU[yOE81QC95MjDo		NGrrUGRqdmS3Y3XzJIFk[3WvdXzheIlwdnNib3[gdFU{NCCyNkOgZY5lKHB5M9Mg	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl2ME[5OUc,OjR7NEC2PVU9N2F-
PBMC	Mn[zSpVv[3Srb36gRZN{[Xl?	M2TyNFUxNzFyMDFOwG0>	NVHV[\|d4OjRiaB?=	MlPGSG1UVw>?	MoezbY5pcWKrdIOgV3RCXDFicHjvd5Bpd3K7bHH0bY9v	NFnrNm09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmxNVg4Oid-MkS5NVE5PzJ:L3G+
MDA-231	M3jWTWZ2dmO2aX;uJGF{e2G7	NWntfnFXOTByIN88US=>	NWfTUVQ5OjRiaB?=	NGr3XWVFVVOR	MmOy[IVkemWjc3XzJGlFVyCneIDy[ZN{cW:w	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlzMUi3Nkc,OjR7MUG4O\|I9N2F-
624.38mel	MmPPSpVv[3Srb36gRZN{[Xl?	MoHLOVAh\|ryP	M1v4b\|I1KGh?	NXTZUJZGTE2VTx?=	M3fGc4Rm[3KnYYPld{BKTE9iZYjwdoV{e2mxbh?=	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlzMUi3Nkc,OjR7MUG4O\|I9N2F-
MDA-231	MWHGeY5kfGmxbjDBd5NigQ>?	MoLDOVAuOjByIN88US=>	MXOyOEBp	NYTSVm5lTE2VTx?=	MlXSbY5pcWKrdIOgTWRQKGGldHn2bZR6KGmwZHXw[Y5l\W62bImgc4YhdVKQQTDs[ZZmdHN?	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlzMUi3Nkc,OjR7MUG4O\|I9N2F-
624.38mel	MkfuSpVv[3Srb36gRZN{[Xl?	M33tXVUxNTJyMDFOwG0>	MmLKNlQhcA>?	MXfEUXNQ	MkLqbY5pcWKrdIOgTWRQKGGldHn2bZR6KGmwZHXw[Y5l\W62bImgc4YhdVKQQTDs[ZZmdHN?	NUGyPGlHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NVE5PzJpPkK0PVEyQDd{PD;hQi=>
HMECs	NFPuO3VHfW6ldHnvckBCe3OjeR?=	NXLt[nZXOTBywrFOwG3DqA>?	M3P6T\|M3yqCq		Mkn4bY5pcWKrdIOgTWZP\|rQEoHHu[EBNWFNiaX7keYNm\CCVVFHUNUBxcG:\|cHjvdplt[XSrb36gZY5lKEmURkGg[ZhxemW\|c3nvci=>	M371eVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MkGxN\|I4Lz5{NEKxNVMzPzxxYU6=
HMECs	NVjpU3dYTnWwY4Tpc44hSXO\|YYm=	M{XFOlExOMLizszNxsA>	M3LBO\|M3yqCq		M1Hvb4lvcGmkaYTzJGlHVs7zwrDt[YRq[XSnZDDwbI9{eGixconsZZRqd25ib3[gV3RCXDFiYX7kJHNVSVR\|LDDieZQhdm:2IH;mJHNVSVR{	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJzMUOyO{c,OjR{MUGzNlc9N2F-
BJAB	MmLXRZBweHSxc3nzJGF{e2G7	NXfvU5lUPcLizszN	NFnpW5YzPCCq		MVTpcoR2[2W\|IHPlcIwh[XCxcITvd4l{	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB3N{G0O{c,OjRyNUexOFc9N2F-
I-83	M2rXe2Fxd3C2b4Ppd{BCe3OjeR?=	NH;Qd3A2yqEQvF2=	M3HTZlI1KGh?		MWDpcoR2[2W\|IHPlcIwh[XCxcITvd4l{	NW\0RXN1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwOVcyPDdpPkK0NFU4OTR5PD;hQi=>
NALM6	M1GxNWFxd3C2b4Ppd{BCe3OjeR?=	M3\5UlXDqM7:TR?=	M2XBbVI1KGh?		MnjEbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>?	M4\mOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEW3NVQ4Lz5{NEC1O\|E1PzxxYU6=
DU-145	M1eyVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{\jXlAuOTBizsznM41t	NIO0S\|I1QCCqwrC=		NGfvZ2pqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd\|NEixOUc,OjN5M{S4NVU9N2F-
Nalm-6	MkD6SpVv[3Srb36gRZN{[Xl?	NGfjZmQyOMLizszN	NGrBeGUyNzJxNDDo		MWDpcoR2[2W\|IHH1eI9xcGGpeR?=	NEXiS2o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[4NVIzOyd-MkO2PFEzOjN:L3G+
Reh	NVXDS21wTnWwY4Tpc44hSXO\|YYm=	NFzieZkyOMLizszN	NUjIeYRiOS9{L{SgbC=>		NVPsXJR3cW6mdXPld{BifXSxcHjh[5k>	NWTOV\|lLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2PFEzOjNpPkKzOlgyOjJ\|PD;hQi=>
Nalm-6	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUTJR\|UxKOLKvEGw5qCK\|ryP	NXX5WGtiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2PFEzOjNpPkKzOlgyOjJ\|PD;hQi=>
Reh	MmrFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUm0W2tEUUN3MDFijNwyOOLCid88US=>	M2HCcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NkixNlI{Lz5{M{[4NVIzOzxxYU6=
HEC1A	NVvzUGtbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3ezOVExOC13MECg{txO	NU\6W3hvOjRiaB?=		Mn;JbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	NVHXe3ptRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1PVU3QTdpPkKzOVk2Pjl5PD;hQi=>
AN3CA	NHy2PWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NY\yN3VmOTByLUWwNEDPxE1?	M{PaUlI1KGh?		MmPMbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzV7NU[5O{c,OjN3OUW2PVc9N2F-
HEC50B	M4TZZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWrJe21[OTByLUWwNEDPxE1?	M1LMXFI1KGh?		NGLCO4xqdmirYnn0d{Bk\WyuIHfyc5d1cCC\|bHnnbJRtgQ>?	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzV7NU[5O{c,OjN3OUW2PVc9N2F-
HEC1A	MVjBdI9xfG:\|aYOgRZN{[Xl?	MYWyNE8yODBizszN	MWSyOEBp		NWnT[WJjcW6mdXPld{BieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	NVzZdYg2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1PVU3QTdpPkKzOVk2Pjl5PD;hQi=>
AN3CA	NFTw[YhCeG:ydH;zbZMhSXO\|YYm=	M1LmZ\|IxNzFyMDFOwG0>	NFO5b\|AzPCCq		NGm3V4dqdmS3Y3XzJIFxd3C2b4Ppd{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzV7NU[5O{c,OjN3OUW2PVc9N2F-
HEC50B	NFH4VJpCeG:ydH;zbZMhSXO\|YYm=	NV7FNVBvOjBxMUCwJO69VQ>?	NELrUGozPCCq		MUfpcoR2[2W\|IHHwc5B1d3OrczDzcIlocHSueR?=	MoDOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3OUW2PVcoRjJ\|NUm1Olk4RC:jPh?=
EHEB	M1KyO2Fxd3C2b4Ppd{BCe3OjeR?=	NGPkNpA1OCEQvF2=	MlXuNlQhcA>?		MorLbY5lfWOnczDhdI9xfG:\|aYO=	NGPjW5M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{S5O\|A4PSd-MkO0PVcxPzV:L3G+
A549	MmjwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWHJR\|UxRTF3LkhCtVIvQCEEtV2=	NEfidVY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{O3O\|E6Oid-MkOzO\|cyQTJ:L3G+
A549 GAPDH-deficient	NH64dWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYXHd29YUUN3ME2xPE42yrF{LkOgxtVO	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzN5N{G5Nkc,OjN\|N{exPVI9N2F-
CLL	NF3scWxCeG:ydH;zbZMhSXO\|YYm=	NGmxOVQyOCEQvF5CpC=>	NWH2VFJ[OjRvOU[gbC=>		NV;oeHZmcW6mdXPld{BieG:ydH;0bYMh[2WubDDk[YF1cA>?	M2LWS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MkC3Olg3Lz5{MkKwO\|Y5PjxxYU6=
MEC1	NGXQTFdCeG:ydH;zbZMhSXO\|YYm=	NHuxSHYyODEEoN88US=>	MmWzO\|IhcA>?		M1HzcYlv\HWlZYOgZZBweHSxc3nzJJNq\26rZnnjZY51dHl?	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjF\|Mkm3N{c,OjJzM{K5O\|M9N2F-
U937	M4PmWGFxd3C2b4Ppd{BCe3OjeR?=	MXSwMlgh\|ryP	NEHiNIk1NTR6IHi=		M{WxUYlv\HWlZYOgZZBweHSxc3nzJJNtcWeqdHz5	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjB5NEewNEc,OjJyN{S3NFA9N2F-
U937	M{PPfWFxd3C2b4Ppd{BCe3OjeR?=	MUCxJO69VQ>?	MWO5OkBp		NHezNIZqdmS3Y3XzJIFxd3C2b4Ppd{B{dGmpaITsfS=>	MkL2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJyMkO1NlMoRjJ{MEKzOVI{RC:jPh?=
Daudi	MlrYRZBweHSxc3nzJGF{e2G7	MV[yNEDPxE1?	NF\KXnQ6PiCq		MVTpcoR2[2W\|IHHwc5B1d3OrczDzcIlocHSueR?=	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjB{M{WyN{c,OjJyMkO1NlM9N2F-
J45.01	NU\HeVFSSXCxcITvd4l{KEG\|c3H5	MYGxJO69VQ>?	NXrpVGVlQTZiaB?=		NHHuSYNqdmS3Y3XzJIFxd3C2b4Ppd{B{dGmpaITsfS=>	M3W5fVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MEKzOVI{Lz5{MkCyN\|UzOzxxYU6=
RPMI 8226	NXfaRnhET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXTKUGliUUN3ME2yOU46yqEEsdMgN{44KM7:TR?=	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTl2OEK2OEc,OjF7NEiyOlQ9N2F-
CEM	M3vy[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlfuTWM2OD1{LkVCpOKyyqByLkSg{txO	NVLBZnk2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG5OFgzPjRpPkKxPVQ5OjZ2PD;hQi=>
Raji	M3SzW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NY\YWXY3UUN3ME2wMlQ4yqEEsdMgNE4xPCEQvF2=	MlTwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF7NEiyOlQoRjJzOUS4NlY1RC:jPh?=
U937	NHK3eGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYnJR\|UxRTBwMkVCpOKyyqByLkC0JO69VQ>?	M1PoT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOUS4NlY1Lz5{MUm0PFI3PDxxYU6=
K562	M3LvN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHvifmhKSzVyPUCuOFTDqMLzwrCwMlA2KM7:TR?=	NXLCOWZrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG5OFgzPjRpPkKxPVQ5OjZ2PD;hQi=>
NALM-6	MX\BdI9xfG:\|aYOgRZN{[Xl?	NH\qW\|kyOCEQvF5CpC=>	MYmyOEBp		MXzpcoR2[2W\|IHPlcIwh[XCxcITvd4l{KHOuaXfoeIx6	M{\GbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNkm5N\|g{Lz5{MU[5PVM5OzxxYU6=
JMV-3	MXLBdI9xfG:\|aYOgRZN{[Xl?	NHu0eHoyOCEQvF5CpC=>	M{O0Z\|I1KGh?		M4n3folv\HWlZYOgZ4VtdCCjcH;weI9{cXNic3zp[4h1dHl?	NInnN3A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MU[5PVM5Oyd-MkG2PVk{QDN:L3G+
EHEB	M1m2XmZ2dmO2aX;uJGF{e2G7	MkDEOU02OCEQvF2=	MVKyOEBp		MVnk[YNz\WG\|ZYOgdFIyKGW6cILld5Nqd25ic3nncolncWOjboTsfS=>	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTF4OEO5NUc,OjFzNkizPVE9N2F-
JVM-2	NXzIdox{TnWwY4Tpc44hSXO\|YYm=	NYXRblJGOzBizszN	NEHFT4IzPCCq		M4fBeYRm[3KnYYPld{BxOjFiZYjwdoV{e2mxbh?=	M4rrTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMU[4N\|kyLz5{MUG2PFM6OTxxYU6=
KBM3/Bu2506	M1jzUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn3HTWMzOD1yLk[3JOK2VQ>?	NGTyfHY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEmzN\|UxQSd-MkC5N\|M2ODl:L3G+
KBM3/Bu2506	M33Ge2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX;pUGd{OC54IN88US=>	NXHKcmh5OjRiaB?=		MXzpcoNz\WG\|ZYOgeIhmKGOnbHyg[pJi[3Srb36gbY4hWy2yaHHz[S=>	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODl\|M{WwPUc,OjB7M{O1NFk9N2F-
MDA-MB-231	NGHkV\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXrJR\|UxRTRwMDFOwG0>	NX74[FNXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC0OFc{QTBpPkKwOFQ4OzlyPD;hQi=>
MCF-7	NIr2TVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3;5emlEPTB;MUWuNEDPxE1?	NFLlfWg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MES0O\|M6OCd-MkC0OFc{QTB:L3G+
HLE-B3	MXXGeY5kfGmxbjDBd5NigQ>?	MWeyOUDPxE1?	MkjmOFghcA>?		M1:5WIJtd2OtczDJSm4u\|rQkgKPpcoR2[2WmIGPURXQyKHCqb4PwbI9zgWyjdHnvckBidmRiSVTPJIV5eHKnc4Ppc44>	M{XiXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNEO1NVU5Lz5{MESzOVE2QDxxYU6=
K562	NF25N4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NFXnSmw4OiCq		NH7GcZFKSzVyPUOuN{BvVQ>?	M3PQU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyM{C3NVk5Lz5{MEOwO\|E6QDxxYU6=
BW-225	MkXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnjCTWMzOD1zLkO3JOOYOTEkiKK4xsDPxE4EoB?=	NXTKfphXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi2OlE{QDBpPkG4OlYyOzhyPD;hQi=>
OH-65	NYPPWmg3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3HqTWlEOjB;MT6zO{DEnzFy4pkSPOKh\|ryPwrC=	NXrXOYc6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi2OlE{QDBpPkG4OlYyOzhyPD;hQi=>
GR-145	MkPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXO1U5B7UUN{ME2yMlc1KMPZIEGw5qiTQCBizszNxsA>	Mn7kQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh4NkGzPFAoRjF6Nk[xN\|gxRC:jPh?=
A549	M3vYVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVSySoF4UUN{ME21MlQ5KMPZIEGw5qiTQCEQvF5CpC=>	M4XJZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6Nk[xN\|gxLz5zOE[2NVM5ODxxYU6=
CaSki	NEHuRY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlHLTWMzOD1zLkO3JOOYKDFy4pkSO{DPxE4EoB?=	M2DNOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6Nk[xN\|gxLz5zOE[2NVM5ODxxYU6=
ZMK-1	NGrD[pZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX;nZZlpUUN{ME2xMlM4KMPZIEGw5qiTPiEQvF5CpC=>	NIe1OGw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOE[2NVM5OCd-MUi2OlE{QDB:L3G+
SKW6.4	NHHHbm5CeG:ydH;zbZMhSXO\|YYm=	NInF[GExNjBzLUGwJO69VQ>?	MXGyOE81QCCq		MUnpcoR2[2W\|IHPlcIwh\GWjdHigbY4h[m:2aDD0bY1mNSCjbnSg[I9{\S1iZHXw[Y5l\W62IH3hco5meg>?	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDB7MkO0NEc,OThyOUKzOFA9N2F-
RPMI 8226	MorYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MX:yOEBp		MmTnTWM2OD1zLkW0xsDPxE1?	MnjqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd7N{[xPFYoRjF5OUe2NVg3RC:jPh?=
MM.1S	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MXy0PEBp		NHr2NpBKSzVyPUGzMlQ5yqEQvF2=	NYLrfIF2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe5O\|YyQDZpPkG3PVc3OTh4PD;hQi=>
MM.1R	NHuyT4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NIqzc2k1QCCq		M1jMbGlEPTB;M{OuO\|kh\|ryP	NEK4R2I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{m3OlE5Pid-MUe5O\|YyQDZ:L3G+
U937	MmPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmfCTWM2OD1\|LEKwNEDDuSB3NkCgcm0>	M2\ybVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF3OUOwN\|YyLz5zNUmzNFM3OTxxYU6=
CLL5	MYLBcpRqfHWvb4KgZZN{[Xl?		Mm\4OFghcHK\|		MnjxRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgR2xNPSClZXzsd{Bqe2:uYYTl[EBnem:vIFPMUEBx[XSrZX70JIF{e2W\|c3XkJIF{KGOnbHygeoli[mmuaYT5JIFnfGW{IES4JIhzeyCkeTDGRWNUKGGwYXz5d4l{NCCHQ{WwJF0hOC5zNjFOwG0v	M3T3TlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkezO\|M6Lz5{NE[3N\|c{QTxxYU6=
K562	NGLkSXNEgXSxdH;4bYNqfHliYYPzZZk>		NXK3OGlFPzJiaILz		NHnHUYdEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBx[WOuaYThfIVtNXKnc3nzeIFvfCCNNU[yJINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSByLkK2JO69VS5?	M1jsd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNkC1OlU3Lz5{ME[wOVY2PjxxYU6=
CLL3	NULF[pR1SW62aYT1cY9zKGG\|c3H5		MX:0PEBpenN?		NGPkWoRCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBEVEx\|IHPlcIx{KGm\|b3zheIVlKG[{b32gR2xNKHCjdHnlcpQh[XO\|ZYPz[YQh[XNiY3XscEB3cWGkaXzpeJkh[W[2ZYKgOFghcHK\|IHL5JGZCS1NiYX7hcJl{cXNuIFXDOVAhRSByLkO1JO69VS5?	NGj6VYk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[3N\|c{QSd-MkS2O\|M4Ozl:L3G+
CLL4	NEO1W2xCdnSrdIXtc5Ih[XO\|YYm=		M3XJV\|Q5KGi{cx?=		MlP2RY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgR2xNPCClZXzsd{Bqe2:uYYTl[EBnem:vIFPMUEBx[XSrZX70JIF{e2W\|c3XkJIF{KGOnbHygeoli[mmuaYT5JIFnfGW{IES4JIhzeyCkeTDGRWNUKGGwYXz5d4l{NCCHQ{WwJF0hOC54NDFOwG0v	M4LrWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkezO\|M6Lz5{NE[3N\|c{QTxxYU6=
CEM-DNR-B	M4\oXGN6fG:2b4jpZ4l1gSCjc4PhfS=>		NH3jRnI4OiCqcoO=		Ml7iR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gR2VONUSQUj3CJINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSBzLkCxJO69VS5?	M3;kSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNkC1OlU3Lz5{ME[wOVY2PjxxYU6=
primary CLL	MUjDfZRwfG:6aXPpeJkh[XO\|YYm=				NHvJco9EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBxemmvYYL5JGNNVCClZXzsd{whVER3MDC9JFEvOSEQvF2u	NWDE[mtVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxOFg{QTJpPkK1NVQ5Ozl{PD;hQi=>
CLL6	MVLBcpRqfHWvb4KgZZN{[Xl?		Ml;POFghcHK\|		NWfVNYRFSW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhS0yONjDj[YxteyCrc3;sZZRm\CCocn;tJGNNVCCyYYTp[Y51KGG\|c3Xzd4VlKGG\|IHPlcIwhfmmjYnnsbZR6KGGodHXyJFQ5KGi{czDifUBHSUOVIHHuZYx6e2m\|LDDFR\|UxKD1iMT62JO69VS5?	NXrmU29ZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2O\|M4OzlpPkK0Olc{PzN7PD;hQi=>
CLL2	NVv0c49CSW62aYT1cY9zKGG\|c3H5		NVTnbVFqPDhiaILz		M2fTPGFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JGNNVDJiY3XscJMhcXOxbHH0[YQh\nKxbTDDUGwheGG2aXXueEBie3Onc4Pl[EBieyClZXzsJJZq[WKrbHn0fUBi\nSncjC0PEBpenNiYomgSmFEWyCjbnHsfZNqeyxiRVO1NEA:KDJwNk[g{txONg>?	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZ5M{ezPUc,OjR4N{O3N\|k9N2F-
HCT116	M{PWUWN6fG:2b4jpZ4l1gSCjc4PhfS=>		NVrwRnVEPzJiaILz		NILwRmxEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJS1RzMU[gZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KFOUQjDhd5NigSxiSVO1NEA:KDZwNjFOwG0v	NITCT3E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUS2NlI4Pyd-MkW0OlIzPzd:L3G+
PBMC	NELFT29EgXSxdH;4bYNqfHliYYPzZZk>		M3LhU\|Q5KGi{cx?=		MnrOR5l1d3SxeHnjbZR6KGGpYXnud5QheGG2aXXueEBRSk2FIHHmeIVzKDR6IHjyd{BjgSCFZXzsWIl1emVvQnz1[UBie3OjeTDpckBxemW\|ZX7jJI9nKG2xdYPlJG0zOTCENDDj[YxteyxiSVO1NEA:KDFyIN88UU4>	Mn;nQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3NkK0NVcoRjJ3NU[yOFE4RC:jPh?=
CHO	MlPnSpVv[3Srb36gZZN{[Xl?				MXrCbY5lcW6pIHHm[olvcXS7IHTleIVzdWmwZXSgZpkh\Gm\|cHzhZ4Vu\W62IH;mJJNx\WOrZnnjJIJqdmSrbnegc4YhYzF{NVndUk0pPC2jbXnuc{0{NWmxZH;wbIVv\XSqeXypMYFl\W6xc3nu[UBqdiCvZX3idoFv\XNib3[gR2hQKGOnbHzzJJN1[WKueTD0doFve2[nY4Tl[EB4cXSqIITo[UBz[XRiYXTlco9{cW6nIFGzJJJm[2WydH;yMEBMcSB;IEGwMlQh\|ryPLh?=	MnXGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwPzdyN{OyNEc,PzdyN{OyNFww[T5?
JVM2	MYHBcpRqfHWvb4KgZZN{[Xl?				NIDRN2tCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDKWm0zKGOnbHzzJIF{e2W\|c3XkJIF{KGOnbHygeoli[mmuaYT5JIFnfGW{IES4JIhzeyCkeTDGRWNUKGGwYXz5d4l{NCCHQ{WwJF0hOTBwNDFOwG0v	MoTwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4N{O3N\|koRjJ2NkezO\|M6RC:jPh?=
HeLa	NIq5Z3ZCdnSrdIXtc5Ih[XO\|YYm=				NFHxcZJCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDI[WxiKGOnbHzzJIF{e2W\|c3XkJIF{KGOnbHygeoli[mmuaYT5JIJ6KE2WVDDhd5NigSxiRVO1NEA:KDF4IN88UU4>	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZ5M{ezPUc,OjR4N{O3N\|k9N2F-
CLL1	NWmxbZRsSW62aYT1cY9zKGG\|c3H5		MnPlOFghcHK\|		MmTyRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgR2xNOSClZXzsd{Bqe2:uYYTl[EBnem:vIFPMUEBx[XSrZX70JIF{e2W\|c3XkJIF{KGOnbHygeoli[mmuaYT5JIFnfGW{IES4JIhzeyCkeTDGRWNUKGGwYXz5d4l{NCCHQ{WwJF0hOTdwMTFOwG0v	M4m4d\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkezO\|M6Lz5{NE[3N\|c{QTxxYU6=
CEM	M37md2N6fG:2b4jpZ4l1gSCjc4PhfS=>		NF;SS2E4OiCqcoO=		NE\BT2dEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBETU1iY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFE6NjR7IN88UU4>	NUC1S2wyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC2NFU3PTZpPkKwOlA2PjV4PD;hQi=>
T47D	M{K3N2N6fG:2b4jpZ4l1gSCjc4PhfS=>		M2DPVFczKGi{cx?=		MnnDR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gWFQ4TCClZXzsd{Bi\nSncjC3NkBpenNiYomgV3JDKGG\|c3H5MEBKSzVyIE2gOFYvOiEQvF2u	Mn3sQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2NkKyO\|coRjJ3NE[yNlc4RC:jPh?=
A549	NF3ScWNEgXSxdH;4bYNqfHliYYPzZZk>		MmHFO\|IhcHK\|		NHrTdZZEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBCPTR7IHPlcIx{KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUCgQUA1Py52NDFOwG0v	NYfrblF2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC2NFU3PTZpPkKwOlA2PjV4PD;hQi=>
CCRF-CEM	NGPpdYtHfW6ldHnvckBie3OjeR?=	NFXDR3YyOCC3TR?=	MnHHNUB1dyB4MDDtbY5{		MkfrSJJ2\yC2cnHud5BwenRiaX6gbJVu[W5iQ1PSSk1ETU1iY3XscJMh[XO\|ZYPz[YQh[XNiRV7UNU1u\WSrYYTl[EB2eHSja3WgZZQhOTBidV2gZYZ1\XJiMTD0c{A3OCCvaX7zJIJ6KGyrcYXp[EB{[2mwdHnscIF1cW:wIHPveY51cW6pIHHuZYx6e2m\|	M4LoOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{i4O\|A2Lz5{M{O4PFcxPTxxYU6=
TC32	NWLreIo1eUiWUzDhd5NigQ>?				NHvWUYtyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiVFOzNkBk\Wyucx?=	M1T0flxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
U-2 OS	M12zUJFJXFNiYYPzZZk>				M2W0SZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCXLUKgU3Mh[2WubIO=	Mne1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
A673	NVnWT4xueUiWUzDhd5NigQ>?				MXfxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSTZ5MzDj[Yxtew>?	M1TLdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
DAOY	MkjCdWhVWyCjc4PhfS=>				MoTMdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKESDT2mgZ4VtdHN?	M4XGb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Saos-2	M4rXTpFJXFNiYYPzZZk>				NYjnfZYyeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGPhc5MuOiClZXzsdy=>	M1LjdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
BT-37	NUDrbFRFeUiWUzDhd5NigQ>?				NXLUXpJieUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IFLUMVM4KGOnbHzz	M3rJZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
RD	NIflZZFyUFSVIHHzd4F6				MlXSdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKGIHPlcIx{	NHexV\|I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
SK-N-SH	MmXadWhVWyCjc4PhfS=>				NFjnNHlyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1utUk1UUCClZXzsdy=>	M4LiXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
MG 63 (6-TG R)	NGL4NZpyUFSVIHHzd4F6				M4mxN5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCPRzC2N{ApPi2WRzDSLUBk\Wyucx?=	NGfYR2g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
BT-12	NYDWXVBleUiWUzDhd5NigQ>?				NXOx[YczeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IFLUMVEzKGOnbHzz	MkPZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
NB1643	MXLxTHRUKGG\|c3H5				NYLLUJZ3eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IF7CNVY1OyClZXzsdy=>	MnS2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
OHS-50	NHHEN\|FyUFSVIHHzd4F6				MkHydWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKE:KUz21NEBk\Wyucx?=	MnjtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
BT-12	M4fme5FJXFNiYYPzZZk>				NX;Dc2FWeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhSlRvMUKgZ4VtdHN?	MmL4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
LAN-5	M2S1ZZFJXFNiYYPzZZk>				NGfZbHNyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBNSU5vNTDj[Yxtew>?	NWn4fHRbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
NB-EBc1	NIP3SYZyUFSVIHHzd4F6				Mo\adWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgUmIuTUKlMTDj[Yxtew>?	NVKwPHVERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
SK-N-SH	NHnhWpNyUFSVIHHzd4F6				MXTxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDTT{1PNVOKIHPlcIx{	NGTVfnc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
Rh41	MVnxTHRUKGG\|c3H5				M1T1fpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCUaESxJINmdGy\|	NUfwSYd4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
A673	MVTxTHRUKGG\|c3H5				NVfsTpNyeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhSTZ5MzDj[Yxteyl?	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
BT-37	M2DDOpFJXFNiYYPzZZk>				MV7xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDCWE0{PyClZXzsdy=>	M2PlNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
MG 63 (6-TG R)	Mk\BdWhVWyCjc4PhfS=>				M2nnOZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJG1IKDZ\|IDi2MXRIKFJrIHPlcIx{	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
Rh30	M1TYWpFJXFNiYYPzZZk>				NEXwN3ZyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBTcDNyIHPlcIx{	M17zWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
U-2 OS	M{jFXJFJXFNiYYPzZZk>				M3jyb5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHUuOiCRUzDj[Yxtew>?	M13wO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
OHS-50	MYDxTHRUKGG\|c3H5				MnXPdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgU2hUNTVyIHPlcIx{	NXf6emx7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
SK-N-SH	MWDxTHRUKGG\|c3H5				NG[0TodyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCRcoToc4dwdmGuIEPEJJZq[WKrbHn0fUB{[3KnZX6g[o9zKFONLV6tV2gh[2WubIO=	MlrnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
RD	NUDzZlAzeUiWUzDhd5NigQ>?				Ml7BdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgVmQh[2WubIO=	M3XWXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Daoy	MlHHdWhVWyCjc4PhfS=>				NFH0ZXpyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCRcoToc4dwdmGuIEPEJJZq[WKrbHn0fUB{[3KnZX6g[o9zKESjb4mgZ4VtdHN?	NF3SUms9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
TC32	M{n2[ZFJXFNiYYPzZZk>				MXTxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBQenSqb3fvcoFtKDOGIHPhd5Bie2Vic3Py[YVvKG[xcjDUR\|MzKGOnbHzz	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
TC32	M3ix[JFJXFNiYYPzZZk>				MYLxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBQenSqb3fvcoFtKDOGII\pZYJqdGm2eTDzZ5Jm\W5iZn;yJHREOzJiY3XscJM>	NX7MdVNyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
MG 63 (6-TG R)	NV7KN\|NLeUiWUzDhd5NigQ>?				MlHIdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohV3K2aH;nc45idCB\|RDD2bYFjcWyrdImgd4Nz\WWwIH\vdkBOTyB4MzCoOk1VTyCUKTDj[Yxtew>?	MmjsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
SJ-GBM2	MmTNdWhVWyCjc4PhfS=>				M2XKV5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSj3HRm0zKGOnbHzz	M2LjNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-MC	M3PUNpFJXFNiYYPzZZk>				NHz0[2lyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1utUk1OSyClZXzsdy=>	MkfuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
NB-EBc1	MnTNdWhVWyCjc4PhfS=>				MYDxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVkJvRVLjNUBk\Wyucx?=	NEf1UGs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
LAN-5	M2P1PZFJXFNiYYPzZZk>				MoX6dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKEyDTj21JINmdGy\|	M2LLTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh18	NFXKbYNyUFSVIHHzd4F6				MUDxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWmhzODDj[Yxtew>?	M1fTeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
NB1643	NUXEU41meUiWUzDhd5NigQ>?				NIHpV3JyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBPSjF4NEOgZ4VtdHN?	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
SK-N-MC	NETzc41yUFSVIHHzd4F6				NYXTd5cxeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhW0tvTj3NR{Bk\Wyucx?=	M2TBdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SJ-GBM2	NVXIOnAyeUiWUzDhd5NigQ>?				NV:xWHVteUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhW0pvR1LNNkBk\Wyucx?=	NEDSNms9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
TC32	NH[3UHByUFSVIHHzd4F6				M1;jcpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHREOzJiY3XscJM>	M3;GflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh18	MmPudWhVWyCjc4PhfS=>				NWP6WmNQeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhWmhzODDj[Yxtew>?	Mkf0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
Saos-2	MoXKdWhVWyCjc4PhfS=>				NWPaXG9yeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhW2Gxcz2yJINmdGy\|	Mn7xQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
SJ-GBM2	NI\MeopyUFSVIHHzd4F6				MkPodWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohV3K2aH;nc45idCB\|RDD2bYFjcWyrdImgd4Nz\WWwIH\vdkBUUi2JQl2yJINmdGy\|	M{HIXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
RD	M2PEWpFJXFNiYYPzZZk>				MljLdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohV3K2aH;nc45idCB\|RDD2bYFjcWyrdImgd4Nz\WWwIH\vdkBTTCClZXzsdy=>	MlPzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	procaspase-9 / procaspase-3; PubMed: 27223263 Oncotarget Procaspase-9 and procaspase-3 were analyzed by Western blot in CLL cells from three patients after a 48 h-incubation in the absence or presence of 3 μM aphidicolin (APC) with or without fludarabine at 0.3 and 1 μM. β-Actin served as a loading control. p-p53 / p53; PubMed: 27223263 Oncotarget (A–B) CLL cells from 3 different patients were incubated for 24 h with fludarabine at the indicated concentrations in the absence or presence of 3 μM aphidicolin (APC). Phosphorylation of p53 at Ser-15 and total p53 were analyzed by Western blot. Data sho䲧疝Ỵ疞㧀疜膉痘 瘿�෋ᾰƌ෋à 㺣痖帉痖Ѐ瑖堘𢡄빢᎒෋à鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒ STAT1; PubMed: 26677135 Int J Mol Med Representative western blot analysis of STAT1 in RAW 264.7 cells treated with STAT1 inhibitor fludarabine (Flu) for 24 h.	27223263 26677135
Immunofluorescence	α-SMA / Vimentin; PubMed: 28322315 Sci Rep FLU (50 μM) reduces the expression of α-SMA and Vimentin protein in primary mouse activated HSCs (Hepatic Stellate Cells).	28322315
Growth inhibition assay	Cell viability ; PubMed: 24956101 PLoS One CLL cells RPMI/0.1% FBS were cultured on 0.5% BSA or 150 nM MMP-9 for 1 h prior to adding the indicated concentrations of fludarabine (Fluda). After 48 h (Fluda) cell viability was determined by flow cytometry using FITC-Annexin V and PI.	24956101

体内研究

PBS对照组中肿瘤细胞增长迅速，25天内扩增为10倍。而用40mg/kgFludarabine处理的肿瘤扩增不超过5倍。40mg/kgFludarabine对RPMI 8226细胞有明显的抗肿瘤效果。RPMI 8226处理肿瘤细胞十天后增加凋亡细胞核数量。^[1] Fludarabine可在免疫缺陷小鼠中有效抑制RPMI 8226细胞的骨髓转移。

细胞实验： ^[1]	- 合并 Cell lines: 地塞米松敏感(MM.1S) 和耐受 (MM.1R) 的人MM 细胞系, RPMI8226和 U266 细胞系 Concentrations: 2 μg/Ml Incubation Time: 24 小时 Method: 对地塞米松敏感(MM.1S) 和耐受 (MM.1R) 的人MM 细胞系, RPMI8226和 U266 细胞系以5 × 10⁵细胞密度铺板，实验组均包括氟达拉滨处理和空白对照组。处理后细胞用PBS清洗两次然后用70%冰乙醇固定，离心后用含100μg/mL核糖核酸酶PBS重悬浮，37ºC孵育30分钟。样品重悬于25μg/mL碘化吡啶中，用流式细胞仪检测。根据产品说明用Annexin V-FITC试剂盒检测细胞凋亡。利用TUNEL（末端脱氧核苷酸转移酶介导脱氧核苷酸缺口末端标记）法和原位细胞凋亡检测试剂盒处理细胞，最后用流式细胞仪分析。 (Only for Reference)
动物实验： ^[1]	- 合并 Animal Models: 携带RPMI 8226肿瘤细胞的免疫缺陷型小鼠 Dosages: 40 mg/kg Administration: 腹腔注射 (Only for Reference)

参考文献

- 合并

溶解度 (25°C)

体外	DMSO	57 mg/mL (199.83 mM)
	Water	Insoluble
	Ethanol	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 5%DMSO+40%PEG300+5%Tween80+50%ddH2O	8 mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Fludarabine (NSC 118218) SDF

分子量	285.23
化学式	C₁₀H₁₂FN₅O₄
CAS号	21679-14-1
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	FaraA, Fludarabinum

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

临床试验信息 (data from https://clinicaltrials.gov, updated on 2021-05-17)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04526795	Not yet recruiting	Drug: Cytarabine\|Drug: Fludarabine\|Drug: Pegcrisantaspase	Blast Phase Chronic Myelogenous Leukemia BCR-ABL1 Positive\|Recurrent Acute Biphenotypic Leukemia\|Recurrent Acute Lymphoblastic Leukemia\|Recurrent Acute Myeloid Leukemia\|Recurrent Chronic Myelogenous Leukemia BCR-ABL1 Positive\|Recurrent T-Cell Prolymphocytic Leukemia\|Refractory Acute Biphenotypic Leukemia\|Refractory Acute Lymphoblastic Leukemia\|Refractory Acute Myeloid Leukemia\|Refractory Chronic Myelogenous Leukemia BCR-ABL1 Positive\|Refractory T-Cell Prolymphocytic Leukemia	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	December 31 2020	Phase 1
NCT03832127	Not yet recruiting	Drug: 18F-Fludarabine	Myeloma	Nantes University Hospital\|Cyceron	April 1 2019	Phase 1
NCT03696537	Active not recruiting	Drug: Fludarabine\|Radiation: Total Marrow Irradiation (TMI)	Acute Myeloid Leukemia\|Chronic Myeloid Leukemia\|Acute Lymphocytic Leukemia\|Myelodysplastic Syndromes	Naoyuki G. Saito M.D. Ph.D.\|Indiana University	August 29 2018	Phase 1
NCT02718755	Withdrawn	Drug: Fludarabine\|Drug: Cytarabine\|Drug: Erwinase	Hematologic Malignancy	M.D. Anderson Cancer Center\|Jazz Pharmaceuticals	May 2018	Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

常见问题及建议解决方法

问题 1：
how to re-suspend and deliver the inhibitor for in vivo experiments?
回答：
For S1491, Fludarabine, we tested a vehicle: 30% Propylene glycol, 5% Tween 80, 65% D5W that you can resuspend the compound in at up to 30mg/ml. It's a suspension and can only be given via oral gavage.

研究领域

产品类型

定制您的化合物库

Fludarabine (NSC 118218)

客户使用Selleck生产的Fludarabine (NSC 118218)发表文献100篇：

产品安全说明书

STAT抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Fludarabine (NSC 118218) SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

临床试验信息 (data from https://clinicaltrials.gov, updated on 2021-05-17)

技术支持

常见问题及建议解决方法

STAT Signaling Pathway Map

相关STAT产品